Psychiatric Bulletin (2006) 30: 55-57. doi: 10.1192/pb.30.2.55
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hodgson, R.
Right arrow Articles by Belgamwar, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hodgson, R.
Right arrow Articles by Belgamwar, R.
Psychiatric Bulletin (2006) 30: 55-57
© 2006 The Royal College of Psychiatrists

Off-label prescribing by psychiatrists

Richard Hodgson, Consultant Psychiatrist

Lyme Brook Mental Health Centre, Bradwell Hospital, Talke Road, Stoke-on-Trent ST5 7TL, e-mail: richarde.hodgson{at}nsch-tr.wmids.nhs.uk

Ravindra Belgamwar, Consultant Psychiatrist

Lyme Brook Mental Health Centre, Stoke-on-Trent

Declaration of interest

This research was funded by an unrestricted grant from Eli Lilly to Richard Hodgson.

AIMS AND METHOD

To report on the use of atypical antipsychotics in one health district by examining secondary care prescribing patterns for these medicines in North Staffordshire between 1994 and 2001. With one exception, these drugs were licensed solely for use in schizophrenia during the study period.

RESULTS

A total of 502 patients were initiated on atypical antipsychotics in the study period. Of these, 297 (59.2%) had a diagnosis of schizophrenia (ICD-10 codes F20-29). Off-label prescribing was common, but psychiatrists were least likely to prescribe clozapine off-label (2.2%). Affective (18.4%) and organic disorders (12.4%) were the main disorders treated off-label. Olanzapine had the highest off-label use (44.5%).

CLINICAL IMPLICATIONS

The high off-label use of atypical antipsychotics has clinical and economic implications. Although off-label prescribing may be in the patient’s best interests, they should be informed and give their consent. Commissioning bodies, such as primary care organisations, are basing their budgets on guidance from the National Institute for Clinical Excellence, which can have implications for funding this off-label use.




This article has been cited by other articles:


Home page
 Psychiatr. Bull.Home page
D. Meagher, A. Pullela, M. Meisinger, N. Geaney, and S. O'Brien
Five-year follow-up of an evidence-based prescribing intervention
Psychiatr. Bull., May 1, 2008; 32(5): 183 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
D. S. Baldwin and N. Kosky
Off-label prescribing in psychiatric practice
Adv. Psychiatr. Treat., November 1, 2007; 13(6): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
R. Hodgson, C. Bushe, and R. Hunter
Measurement of long-term outcomes in observational and randomised controlled trials
The British Journal of Psychiatry, August 1, 2007; 191(50): s78 - s84.
[Abstract] [Full Text] [PDF]

Home page
 Qual Saf Health CareHome page
I. D Maidment, P. Lelliott, and C. Paton
Medication errors in mental healthcare: a systematic review
Qual. Saf. Health Care, December 1, 2006; 15(6): 409 - 413.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Off label prescribing by child and adolescent psychiatrists
Anne Thompson, et al.
PB Online, 14 Jul 2006 [Full text]